Lori Ferris
About Lori Ferris
Lori Ferris serves as the Senior Director at Lyndra Therapeutics, where she specializes in pre-clinical formulation and solid form strategy. With a strong background in pharmaceutical sciences and a focus on chemistry, she has held various roles in the industry, including positions at Vertex Pharmaceuticals.
Current Role at Lyndra Therapeutics
Lori Ferris serves as Senior Director at Lyndra Therapeutics, a position she has held since 2023. In this role, she focuses on pre-clinical formulation and solid form strategy, overseeing projects from early research through development and into commercial stages. Her expertise contributes to the advancement of innovative therapeutic solutions at the company.
Previous Experience at Lyndra Therapeutics
Before her current role, Lori Ferris worked at Lyndra Therapeutics as Director of Formulation from 2021 to 2024. During her three-year tenure, she played a key role in developing formulation strategies that support the company’s mission to improve patient adherence through innovative drug delivery systems.
Experience at Vertex Pharmaceuticals
Lori Ferris has significant experience from her time at Vertex Pharmaceuticals, where she held various positions from 2016 to 2021. She started as Scientist II and progressed to Senior Scientist, and briefly served as Principal Research Scientist. Her work at Vertex involved contributions to pharmaceutical development, enhancing her expertise in the field.
Educational Background in Chemistry
Lori Ferris has a strong academic foundation in chemistry. She earned her Bachelor of Science degree from Worcester Polytechnic Institute, followed by a Master’s degree from Yale University. Her education provided her with a solid grounding in pharmaceutical sciences, which she has applied throughout her career.
Graduate Studies at Yale University
During her time at Yale University, Lori Ferris completed her graduate studies in chemistry from 2007 to 2009. This experience included working as a Graduate Student from 2007 to 2010, where she engaged in research that further developed her skills and knowledge in the field of pharmaceutical sciences.